Scynexis Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.385
- Today's High:
- $3.58
- Open Price:
- $3.41
- 52W Low:
- $1.15
- 52W High:
- $3.87
- Prev. Close:
- $3.41
- Volume:
- 294583
Company Statistics
- Market Cap.:
- $126.77 million
- Book Value:
- 2.504
- Revenue TTM:
- $135.66 million
- Operating Margin TTM:
- 45.37%
- Gross Profit TTM:
- $12.85 million
- Profit Margin:
- 32.71%
- Return on Assets TTM:
- 26.49%
- Return on Equity TTM:
- 64.05%
Company Profile
Scynexis Inc had its IPO on 2014-05-02 under the ticker symbol SCYX.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Scynexis Inc has a staff strength of 36 employees.
Stock update
Shares of Scynexis Inc opened at $3.41 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.39 - $3.58, and closed at $3.51.
This is a +2.93% increase from the previous day's closing price.
A total volume of 294,583 shares were traded at the close of the day’s session.
In the last one week, shares of Scynexis Inc have slipped by -3.7%.
Scynexis Inc's Key Ratios
Scynexis Inc has a market cap of $126.77 million, indicating a price to book ratio of 3.9092 and a price to sales ratio of 15.058.
In the last 12-months Scynexis Inc’s revenue was $135.66 million with a gross profit of $12.85 million and an EBITDA of $62.16 million. The EBITDA ratio measures Scynexis Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Scynexis Inc’s operating margin was 45.37% while its return on assets stood at 26.49% with a return of equity of 64.05%.
In Q2, Scynexis Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 9836.1%.
Scynexis Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 3.7065
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0.92 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Scynexis Inc’s profitability.
Scynexis Inc stock is trading at a EV to sales ratio of 4.7177 and a EV to EBITDA ratio of -0.2552. Its price to sales ratio in the trailing 12-months stood at 15.058.
Scynexis Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $154.86 million
- Total Liabilities
- $16.16 million
- Operating Cash Flow
- $-6384000.00
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Scynexis Inc ended 2024 with $154.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $154.86 million while shareholder equity stood at $93.08 million.
Scynexis Inc ended 2024 with $1.14 million in deferred long-term liabilities, $16.16 million in other current liabilities, 40000.00 in common stock, $-333904000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $57.91 million and cash and short-term investments were $85.54 million. The company’s total short-term debt was $310,000 while long-term debt stood at $11.63 million.
Scynexis Inc’s total current assets stands at $145.53 million while long-term investments were $6.34 million and short-term investments were $27.64 million. Its net receivables were $46.59 million compared to accounts payable of $3.42 million and inventory worth $10.29 million.
In 2024, Scynexis Inc's operating cash flow was $-6384000.00 while its capital expenditure stood at $0.
Comparatively, Scynexis Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.51
- 52-Week High
- $3.87
- 52-Week Low
- $1.15
- Analyst Target Price
- $14.5
Scynexis Inc stock is currently trading at $3.51 per share. It touched a 52-week high of $3.87 and a 52-week low of $3.87. Analysts tracking the stock have a 12-month average target price of $14.5.
Its 50-day moving average was $3.01 and 200-day moving average was $2.43 The short ratio stood at 3.96 indicating a short percent outstanding of 0%.
Around 139.5% of the company’s stock are held by insiders while 4886.3% are held by institutions.
Frequently Asked Questions About Scynexis Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.